European Union (EU) pharmaceutical legislation known as the Clinical Trials Regulation entered into force from 31 January 2023. It aims to ensure the EU offers an attractive and favourable environment for carrying out clinical research on a large scale, with high standards of public transparency and safety for clinical trial participants.
The EU Clinical Trials Regulation (EU CTR) repealed the Clinical Trials Directive (EC) No. 2001/20/EC and national implementing legislation in the EU Member States, which regulated clinical trials in the EU until the Regulation’s entry into application.
On 31 January 2023, the use of the Clinical Trials Information System (CTIS) will become mandatory for new clinical trial applications and will serve as the single-entry point for submission by sponsors and for regulatory assessment.
Consult the Regulation:
See more details on EMA website, link.
The European Medicines Agency (EMA) has released a draft guideline on the medical device quality…
EMA has recently published the first of a series of guidance documents to help applicants…
On 1st of Feb. 2019 the FDA announced the availability of draft guidance "Rare Diseases:…
The sponsor should ensure that all trial-related tasks, which are outsourced to the contract research…
Trial master file (TMF) plays a key role in the successful management of a trial…
A new European Medicines Agency (EMA) guideline on Good Pharmacovigilance Practices (GVP) came into effect…